| Hazard Information | Back Directory | [Uses]
CWI1-2 hydrochloride is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects[1]. | [Biological Activity]
CWI1-2 is a cell penetrantpotent and selective inhibitor of an m6A reader IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2). CWI1-2 potently inhibits IGF2BP2 interaction with N6-Methyladenosine (m6A) modified target transcripts. CWI1-2 exhibits potent anti-leukemia efficacy in vitro and in vivo. | [in vivo]
CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) hydrochloride can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight[1].
| [References]
[1] Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. DOI:10.1016/j.ccell.2022.10.004 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|